合并症和并发症对 COVID-19 严重程度的影响和发生率与年龄、性别、肥胖和原有吸烟情况的关系:荟萃分析。

IF 2.1 Q2 MEDICINE, GENERAL & INTERNAL
BioMedicine-Taiwan Pub Date : 2024-03-01 eCollection Date: 2024-01-01 DOI:10.37796/2211-8039.1429
Soulandi Djorwé, Amale Bousfiha, Néhémie Nzoyikorera, Joseph Nyandwi, Bellamine Kawthar, Abderrahim Malki
{"title":"合并症和并发症对 COVID-19 严重程度的影响和发生率与年龄、性别、肥胖和原有吸烟情况的关系:荟萃分析。","authors":"Soulandi Djorwé, Amale Bousfiha, Néhémie Nzoyikorera, Joseph Nyandwi, Bellamine Kawthar, Abderrahim Malki","doi":"10.37796/2211-8039.1429","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 patients usually present multiple comorbidities and complications associated with severe forms of SARS-CoV-2 infection. This study aimed to assess the risk factors and prevalence of comorbidities and complications contributing to the severity of COVID-19.</p><p><strong>Methods: </strong>This meta-analysis was performed according to PRISMA guidelines. We searched various databases, including PubMed, Google Scholar, and Scopus (between 2020 and 2023), for eligible studies for this meta-analysis.</p><p><strong>Results: </strong>Thirty-three studies were eligible, including 85,812 patients, of which 36 % (30,634/85,812) had severe disease, whereas 64 % (55,178/85,812) had non-severe disease. Severe cases were potentially correlated with the following factors: gender (male) (odd ratio (OR) = 1.52, 95 % CI: 1.34-1.73), advanced age (OR = 3.06, 95 % CI: 2.18-4.40) pre-existing smoking (OR = 1.33, 95 % CI: 1.01-1.75), obesity (OR = 2.11, 95 % CI: 1.47-3.04), diabetes (OR = 1.81, 95 % CI: 1.35-2.43), hypertension (OR = 2.22, 95 % CI: 1.72-2.87), coronary heart disease (OR = 2.17, 95 % CI: 1.42-3.31), CKD (OR = 2.27, 95 % CI: 1.26-4.06), COPD (OR = 1.95, 95 % CI: 1.22-3.09), malignancy (OR = 1.63, 95 % CI: 1.07-2.49) and cerebrovascular disease (OR = 2.76, 95 % CI: 1.63-4.62). All these comorbidities were significantly higher in the severe COVID-19 group compared with the non-severe COVID-19 group. In addition, the most severe complications were associated with shock (OR = 28.08, 95 % CI: 3.49-226.03), ARDS (OR = 13.09, 95 % CI: 5.87-29.18), AKI (OR = 16.91, 95 % CI: 1.87-152.45) and arrhythmia (OR = 7.47, 95 % CI: 2.96-18.83). However, these complications were the most likely to prevent recovery in patients with severe affections compared with non-severe affection groups.</p><p><strong>Conclusion: </strong>All the comorbidities and complications listed above are more likely to cause severe forms of COVID-19 in some patients and hinder recovery. They are therefore risk factors to be controlled to minimize the undesirable effects of the disease.</p>","PeriodicalId":51650,"journal":{"name":"BioMedicine-Taiwan","volume":"14 1","pages":"20-38"},"PeriodicalIF":2.1000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962561/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact and prevalence of comorbidities and complications on the severity of COVID-19 in association with age, gender, obesity, and pre-existing smoking: A meta-analysis.\",\"authors\":\"Soulandi Djorwé, Amale Bousfiha, Néhémie Nzoyikorera, Joseph Nyandwi, Bellamine Kawthar, Abderrahim Malki\",\"doi\":\"10.37796/2211-8039.1429\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>COVID-19 patients usually present multiple comorbidities and complications associated with severe forms of SARS-CoV-2 infection. This study aimed to assess the risk factors and prevalence of comorbidities and complications contributing to the severity of COVID-19.</p><p><strong>Methods: </strong>This meta-analysis was performed according to PRISMA guidelines. We searched various databases, including PubMed, Google Scholar, and Scopus (between 2020 and 2023), for eligible studies for this meta-analysis.</p><p><strong>Results: </strong>Thirty-three studies were eligible, including 85,812 patients, of which 36 % (30,634/85,812) had severe disease, whereas 64 % (55,178/85,812) had non-severe disease. Severe cases were potentially correlated with the following factors: gender (male) (odd ratio (OR) = 1.52, 95 % CI: 1.34-1.73), advanced age (OR = 3.06, 95 % CI: 2.18-4.40) pre-existing smoking (OR = 1.33, 95 % CI: 1.01-1.75), obesity (OR = 2.11, 95 % CI: 1.47-3.04), diabetes (OR = 1.81, 95 % CI: 1.35-2.43), hypertension (OR = 2.22, 95 % CI: 1.72-2.87), coronary heart disease (OR = 2.17, 95 % CI: 1.42-3.31), CKD (OR = 2.27, 95 % CI: 1.26-4.06), COPD (OR = 1.95, 95 % CI: 1.22-3.09), malignancy (OR = 1.63, 95 % CI: 1.07-2.49) and cerebrovascular disease (OR = 2.76, 95 % CI: 1.63-4.62). All these comorbidities were significantly higher in the severe COVID-19 group compared with the non-severe COVID-19 group. In addition, the most severe complications were associated with shock (OR = 28.08, 95 % CI: 3.49-226.03), ARDS (OR = 13.09, 95 % CI: 5.87-29.18), AKI (OR = 16.91, 95 % CI: 1.87-152.45) and arrhythmia (OR = 7.47, 95 % CI: 2.96-18.83). However, these complications were the most likely to prevent recovery in patients with severe affections compared with non-severe affection groups.</p><p><strong>Conclusion: </strong>All the comorbidities and complications listed above are more likely to cause severe forms of COVID-19 in some patients and hinder recovery. They are therefore risk factors to be controlled to minimize the undesirable effects of the disease.</p>\",\"PeriodicalId\":51650,\"journal\":{\"name\":\"BioMedicine-Taiwan\",\"volume\":\"14 1\",\"pages\":\"20-38\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962561/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BioMedicine-Taiwan\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37796/2211-8039.1429\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioMedicine-Taiwan","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37796/2211-8039.1429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:COVID-19患者通常伴有多种合并症和并发症,与严重的SARS-CoV-2感染相关。本研究旨在评估导致 COVID-19 严重程度的合并症和并发症的风险因素和患病率:本荟萃分析根据 PRISMA 指南进行。我们检索了各种数据库,包括 PubMed、Google Scholar 和 Scopus(2020 年至 2023 年),寻找符合荟萃分析条件的研究:符合条件的研究有 33 项,包括 85,812 名患者,其中 36% (30,634/85,812)的患者病情严重,而 64% (55,178/85,812)的患者病情不严重。重症病例可能与以下因素有关:性别(男性)(奇数比 (OR) = 1.52,95 % CI:1.34-1.73)、高龄(OR = 3.06,95 % CI:2.18-4.40)、吸烟(OR = 1.33,95 % CI:1.01-1.75)、肥胖(OR = 2.11,95 % CI:1.47-3.04)、糖尿病(OR = 1.81,95 % CI:1.35-2.43)、高血压(OR = 2.22,95 % CI:1.72-2.87)、冠心病(OR = 2.17,95 % CI:1.42-3.31)、慢性肾脏病(OR = 2.27,95 % CI:1.26-4.06)、慢性阻塞性肺病(OR = 1.95,95 % CI:1.22-3.09)、恶性肿瘤(OR = 1.63,95 % CI:1.07-2.49)和脑血管疾病(OR = 2.76,95 % CI:1.63-4.62)。与非重度 COVID-19 组相比,重度 COVID-19 组的所有这些并发症发生率都明显较高。此外,最严重的并发症与休克(OR = 28.08,95 % CI:3.49-226.03)、ARDS(OR = 13.09,95 % CI:5.87-29.18)、AKI(OR = 16.91,95 % CI:1.87-152.45)和心律失常(OR = 7.47,95 % CI:2.96-18.83)有关。然而,与非严重影响组相比,这些并发症最有可能阻碍严重影响组患者的康复:结论:上述所有合并症和并发症在某些患者中更有可能导致严重的 COVID-19 并阻碍康复。因此,应控制这些风险因素,以尽量减少疾病的不良影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact and prevalence of comorbidities and complications on the severity of COVID-19 in association with age, gender, obesity, and pre-existing smoking: A meta-analysis.

Background: COVID-19 patients usually present multiple comorbidities and complications associated with severe forms of SARS-CoV-2 infection. This study aimed to assess the risk factors and prevalence of comorbidities and complications contributing to the severity of COVID-19.

Methods: This meta-analysis was performed according to PRISMA guidelines. We searched various databases, including PubMed, Google Scholar, and Scopus (between 2020 and 2023), for eligible studies for this meta-analysis.

Results: Thirty-three studies were eligible, including 85,812 patients, of which 36 % (30,634/85,812) had severe disease, whereas 64 % (55,178/85,812) had non-severe disease. Severe cases were potentially correlated with the following factors: gender (male) (odd ratio (OR) = 1.52, 95 % CI: 1.34-1.73), advanced age (OR = 3.06, 95 % CI: 2.18-4.40) pre-existing smoking (OR = 1.33, 95 % CI: 1.01-1.75), obesity (OR = 2.11, 95 % CI: 1.47-3.04), diabetes (OR = 1.81, 95 % CI: 1.35-2.43), hypertension (OR = 2.22, 95 % CI: 1.72-2.87), coronary heart disease (OR = 2.17, 95 % CI: 1.42-3.31), CKD (OR = 2.27, 95 % CI: 1.26-4.06), COPD (OR = 1.95, 95 % CI: 1.22-3.09), malignancy (OR = 1.63, 95 % CI: 1.07-2.49) and cerebrovascular disease (OR = 2.76, 95 % CI: 1.63-4.62). All these comorbidities were significantly higher in the severe COVID-19 group compared with the non-severe COVID-19 group. In addition, the most severe complications were associated with shock (OR = 28.08, 95 % CI: 3.49-226.03), ARDS (OR = 13.09, 95 % CI: 5.87-29.18), AKI (OR = 16.91, 95 % CI: 1.87-152.45) and arrhythmia (OR = 7.47, 95 % CI: 2.96-18.83). However, these complications were the most likely to prevent recovery in patients with severe affections compared with non-severe affection groups.

Conclusion: All the comorbidities and complications listed above are more likely to cause severe forms of COVID-19 in some patients and hinder recovery. They are therefore risk factors to be controlled to minimize the undesirable effects of the disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BioMedicine-Taiwan
BioMedicine-Taiwan MEDICINE, GENERAL & INTERNAL-
CiteScore
2.80
自引率
5.90%
发文量
21
审稿时长
24 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信